

IL28B polymorphism is associated with treatment response in chronic hepatitis C

Journal of Hepatology

56, 527-532

DOI: [10.1016/j.jhep.2011.09.008](https://doi.org/10.1016/j.jhep.2011.09.008)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immune-Related Disorders and Extrahepatic Diseases in Chronic HCV Infection. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	4
2	IL28B Polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. <i>Hepatitis Monthly</i> , 2012, 11, 958-959.	0.1	15
3	The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	26
4	Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 722-728.	1.0	31
5	Focusing on the patient: impact of new UK guidelines on treatment of chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 259-261.	1.4	0
6	Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?. <i>Antiviral Therapy</i> , 2012, 17, 1163-1170.	0.6	7
7	Hepatitis C virus genotype 5: an orphan virus. <i>Antiviral Therapy</i> , 2012, 18, 263-269.	0.6	4
8	Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 677-684.	1.0	33
9	A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping. <i>Journal of Hepatology</i> , 2012, 56, 1230-1238.	1.8	19
10	The impact of organ dysfunction in cirrhosis: Survival at a cost?. <i>Journal of Hepatology</i> , 2012, 57, 707-708.	1.8	2
11	Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2012, 57, 706.	1.8	0
12	Reply to "Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C" <i>Journal of Hepatology</i> , 2012, 57, 706-707.	1.8	0
13	NS5A Sequence Heterogeneity of Hepatitis C Virus Genotype 4a Predicts Clinical Outcome of Pegylated-Interferon/Ribavirin Therapy in Egyptian Patients. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3886-3892.	1.8	17
14	Host Genetic Variants in the Pathogenesis of Hepatitis C. <i>Viruses</i> , 2012, 4, 3281-3302.	1.5	38
15	Genetic Factors and Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2012, 142, 1335-1339.	0.6	16
16	Interferon Stimulated Genes and Hepatitis C Virus Infection. <i>Journal of Interferon and Cytokine Research</i> , 2012, 32, 557-562.	0.5	0
17	IL28B: Current and Future Use. <i>Current Hepatitis Reports</i> , 2012, 11, 136-145.	0.3	0
18	IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 863-877.	1.9	12

#	ARTICLE	IF	CITATIONS
19	An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 359-375.	1.8	101
20	Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?. <i>Journal of Medical Virology</i> , 2012, 84, 1217-1223.	2.5	14
21	Genetics of IL28B and HCV response to infection and treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 406-417.	8.2	94
22	What's new in HCV genotype 2 treatment. <i>Liver International</i> , 2012, 32, 135-140.	1.9	14
23	IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?. <i>Liver International</i> , 2012, 32, 74-78.	1.9	19
24	Response-guided and unguided treatment of chronic hepatitis C. <i>Liver International</i> , 2012, 32, 64-73.	1.9	12
25	Hepatitis C virus treatment pre- and post-liver transplantation. <i>Liver International</i> , 2012, 32, 120-128.	1.9	62
26	A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome. <i>Journal of Virological Methods</i> , 2012, 184, 93-97.	1.0	12
27	Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1434-1442.	1.9	35
28	Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon and ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 91-103.	1.9	55
29	Hepatitis C therapy in non-genotype 1 patients: the near future. <i>Journal of Viral Hepatitis</i> , 2012, 19, 525-536.	1.0	23
30	Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. <i>BMC Medicine</i> , 2013, 11, 6.	2.3	80
31	IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. <i>Hepatology International</i> , 2013, 7, 533-538.	1.9	24
32	Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance. <i>Infection, Genetics and Evolution</i> , 2013, 19, 113-119.	1.0	19
33	Sofosbuvir-based interferon-free therapy for patients with HCV infection. <i>Journal of Hepatology</i> , 2013, 59, 1342-1345.	1.8	16
34	Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 470-477.	1.0	24
35	Treatment as prevention and cure towards global eradication of hepatitis C virus. <i>Trends in Microbiology</i> , 2013, 21, 625-633.	3.5	56
36	The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. <i>Virology</i> , 2013, 444, 292-300.	1.1	28

#	ARTICLE	IF	CITATIONS
37	Cytokines genes polymorphisms in chronic hepatitis C: Impact on susceptibility to infection and response to therapy. <i>Cytokine</i> , 2013, 61, 478-484.	1.4	46
38	Association between an IL28B genetic polymorphism and the efficacy of the response-guided pegylated interferon therapy in children with chronic hepatic C infection. <i>Hepatology Research</i> , 2013, 43, 327-338.	1.8	10
39	IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. <i>Journal of Viral Hepatitis</i> , 2013, 20, 59-64.	1.0	39
40	How to optimize HCV therapy in genotype 2 patients. <i>Liver International</i> , 2013, 33, 35-40.	1.9	14
41	How to optimize HCV therapy in genotype 4 patients. <i>Liver International</i> , 2013, 33, 41-45.	1.9	14
42	Best strategies for global HCV eradication. <i>Liver International</i> , 2013, 33, 68-79.	1.9	97
43	Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?. <i>Liver International</i> , 2013, 33, 105-110.	1.9	26
44	Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 262-268.	0.7	20
45	Single Nucleotide Polymorphisms of IL10 and IL28B as Predictors of the Response of IFN Therapy in HCV Genotype 4 Infected Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 57, 155-160.	0.9	21
46	Endogenous IFN λ 3 in chronic HCV genotype 4 patients treated with PEG-IFN λ 2 and ribavirin. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 859-867.	0.5	3
47	The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis. <i>Hepatitis Monthly</i> , 2013, 13, e10509.	0.1	17
48	Prediction of sustained virologic responses to combination therapy of pegylated interferon- λ 2 and ribavirin in patients with chronic hepatitis C infection. <i>Journal of Family and Community Medicine</i> , 2013, 20, 35.	0.5	21
49	Insulin resistance. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 421-427.	0.8	15
50	Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2013, 8, e77530.	1.1	8
51	IL-28B Polymorphisms Correlated with Treatment Response in HCV-4 Mono-Infected Patients: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e91316.	1.1	7
52	Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. <i>Genes and Immunity</i> , 2014, 15, 88-94.	2.2	19
53	Optimal Management of HCV Genotype 4. <i>Current Hepatology Reports</i> , 2014, 13, 286-294.	0.4	0
54	Interleukin 28B Polymorphisms and Therapy Response in Egyptian Hepatitis C Genotype-4 Patients. <i>DNA and Cell Biology</i> , 2014, 33, 642-646.	0.9	2

#	ARTICLE	IF	CITATIONS
55	The Association of IL28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent. <i>International Journal of Molecular Sciences</i> , 2014, 15, 7213-7224.	1.8	19
56	Reduction of MicroRNA 122 Expression in <i>IFNL3</i> CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C. <i>Journal of Virology</i> , 2014, 88, 6394-6402.	1.5	29
57	<i>IFNL3</i> (<i>IL28B</i>) polymorphism does not predict long-term response to interferon therapy in <i>HBsAg</i> -positive chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 525-532.	1.0	26
58	Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1458-1462.	1.4	4
59	Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan. <i>Hepatology Research</i> , 2014, 44, 983-992.	1.8	3
60	Viral hepatitis: Impressive advances but still a long way to eradication of the disease. <i>Liver International</i> , 2014, 34, 1-3.	1.9	8
61	HCV direct-acting antiviral agents: the best interferon-free combinations. <i>Liver International</i> , 2014, 34, 69-78.	1.9	213
62	Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity. <i>Liver International</i> , 2014, 34, 1447-1451.	1.9	16
63	Meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1189-1201.	0.8	4
64	Prior to the Oral Therapy, What Do We Know About HCV-4 in Egypt. <i>Medicine (United States)</i> , 2014, 93, e204.	0.4	26
65	Recurrent Painful Perianal Subcutaneous Angiomatoid Fibrous Histiocytoma. <i>Medicine (United States)</i> , 2014, 93, e202.	0.4	2
66	Daclatasvir plus sofosbuvir for HCV infection: An oral combination therapy with high antiviral efficacy. <i>Journal of Hepatology</i> , 2014, 61, 435-438.	1.8	36
67	Identification of naïve HCV-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. <i>Antiviral Research</i> , 2014, 106, 105-110.	1.9	9
68	Role of <i>IL28B</i> for chronic hepatitis C treatment toward personalized medicine. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 241-249.	1.4	49
69	Validation of interleukin 28B genotyping assay for clinical use. <i>Clinical Biochemistry</i> , 2014, 47, 478-480.	0.8	3
70	Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 137-147.	1.9	74
71	Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 25-38.	1.6	2
72	Association of <i>IL28B</i> Polymorphism with Fibrosis, Liver Inflammation, Gender Respective Natural History of Hepatitis C Virus in Egyptian Patients with Genotype 4. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 22-27.	0.5	9

#	ARTICLE	IF	CITATIONS
73	Predictors of the therapeutic response in hepatitis C. A 2013 update. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 12-17.	0.7	7
74	Sofosbuvir for the treatment of hepatitis C virus. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 121-130.	0.9	62
75	HCV cirrhosis at the edge of decompensation: Will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?. <i>Journal of Hepatology</i> , 2014, 61, 1430-1433.	1.8	12
76	The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. <i>Pharmacotherapy</i> , 2014, 34, 185-201.	1.2	11
77	Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. <i>Liver International</i> , 2014, 34, 60-68.	1.9	50
78	The Efficacy of a <i>Hansenula</i> -Derived 20kDa Pegylated Interferon Alpha-2a in the Treatment of Genotype 4 Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 727-733.	0.5	3
80	Genetic Variants at the <i>IFNL3</i> Locus and Their Association with Hepatitis C Virus Infections Reveal Novel Insights into Host-Virus Interactions. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 479-497.	0.5	17
81	The current and future disease burden of chronic hepatitis C virus infection in Egypt. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 45-52.	0.4	88
82	Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. <i>Hepatic Medicine: Evidence and Research</i> , 2014, 6, 61.	0.9	27
83	Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000049.	1.1	13
84	Hepatitis C genotype 4: The past, present, and future. <i>World Journal of Hepatology</i> , 2015, 7, 2792.	0.8	41
85	IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0121395.	1.1	8
86	Prevalence of Thymine-Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection. <i>PLoS ONE</i> , 2015, 10, e0125400.	1.1	7
87	Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients. <i>Cytokine</i> , 2015, 74, 268-272.	1.4	3
88	Epstein-Barr virus and Interleukin-28B polymorphism in the prediction of response to interferon therapy in hepatitis C patients. <i>Arab Journal of Gastroenterology</i> , 2015, 16, 84-89.	0.4	1
89	Optimal therapy in genotype 4 chronic hepatitis C: finally cured?. <i>Liver International</i> , 2015, 35, 27-34.	1.9	29
90	Viral hepatitis: towards the eradication of HCV and a cure for HBV. <i>Liver International</i> , 2015, 35, 1-3.	1.9	1
91	IL28Br12980275 polymorphism shows association with response to treatment in Pakistani patients with Chronic Hepatitis C. <i>Journal of Medical Virology</i> , 2015, 87, 814-820.	2.5	10

#	ARTICLE	IF	CITATIONS
92	Optimal <sc>IFN</sc>-free therapy in treatment-naïve patients with <sc>HCV</sc> genotype 1 infection. <i>Liver International</i> , 2015, 35, 56-64.	1.9	27
93	Precore/Core promoter variants to predict significant fibrosis in both <sc>HB</sc>eAg positive and negative chronic hepatitis B. <i>Liver International</i> , 2015, 35, 2082-2089.	1.9	21
94	Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. <i>Journal of Hepatology</i> , 2015, 62, 1047-1055.	1.8	76
95	Genetic variations of IL-28B and PD-1 are in association with the susceptibility and outcomes of HCV infection in Southeast China. <i>Infection, Genetics and Evolution</i> , 2015, 32, 89-96.	1.0	16
96	HCV F protein amplifies the predictions of IL-28B and CTLA-4 polymorphisms about the susceptibility and outcomes of HCV infection in Southeast China. <i>Infection, Genetics and Evolution</i> , 2015, 34, 52-60.	1.0	1
97	Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population. <i>Journal of Clinical Virology</i> , 2015, 69, 184-189.	1.6	4
98	P53 rs1042522 and CD95 rs1800682 genetic variations in HCV-4a response to antiviral therapy. <i>Genes and Diseases</i> , 2015, 2, 197-210.	1.5	2
99	Differential distribution of IL28B.rs12979860 single-nucleotide polymorphism among Egyptian healthcare workers with and without a hepatitis C virus-specific cellular immune response. <i>Archives of Virology</i> , 2015, 160, 1741-1750.	0.9	12
100	Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4. <i>Cytokine</i> , 2015, 75, 349-355.	1.4	3
101	Optimism for patients with genotype 4 HCV infection: Clinical trials with direct-acting antivirals finally available. <i>Journal of Hepatology</i> , 2015, 62, 996-999.	1.8	5
102	Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. <i>Hepatology International</i> , 2015, 9, 251-257.	1.9	14
103	A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin. <i>Journal of Medical Virology</i> , 2015, 87, 1716-1721.	2.5	3
104	Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. <i>Lancet, The</i> , 2015, 385, 2502-2509.	6.3	245
105	Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection. <i>Archives of Virology</i> , 2015, 160, 2833-2837.	0.9	16
106	Role of IL-28B polymorphisms in virologic response to combined pegylated interferon and ribavirin therapy in genotype 4 chronic HCV infected patients with and without cirrhosis. <i>Alexandria Journal of Medicine</i> , 2015, 51, 231-239.	0.4	3
107	Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 859-870.	1.0	13
108	Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. <i>Journal of Hepatology</i> , 2015, 62, 1040-1046.	1.8	133
109	Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. <i>Critical Reviews in Microbiology</i> , 2016, 42, 535-547.	2.7	33

#	ARTICLE	IF	CITATIONS
110	Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent. <i>Indian Journal of Medical Microbiology</i> , 2016, 34, 335-341.	0.3	4
111	IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. <i>SpringerPlus</i> , 2016, 5, 1990.	1.2	11
112	Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. <i>Journal of Medical Virology</i> , 2016, 88, 481-486.	2.5	6
113	Targeting IFN- β : therapeutic implications. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1425-1432.	1.5	19
114	Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. <i>Advances in Therapy</i> , 2016, 33, 1797-1813.	1.3	2
115	Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. <i>Hepatology</i> , 2016, 64, 1049-1056.	3.6	106
116	Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 25-35.	3.7	45
117	Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C. , 2016, , 225-241.		0
118	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 953-960.	0.8	6
119	Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 149-158.	0.5	4
120	Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current <sc>IFN</sc>-free treatment and future perspectives. <i>Liver International</i> , 2016, 36, 47-57.	1.9	193
121	Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , 2016, 16, 18-29.	0.9	10
122	Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. <i>Journal of Immigrant and Minority Health</i> , 2017, 19, 876-882.	0.8	2
123	Simeprevir in combination with sofosbuvir in treatment-naïve and experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 468-475.	1.9	30
124	Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. <i>PLoS ONE</i> , 2017, 12, e0168713.	1.1	6
125	Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. <i>Liver International</i> , 2018, 38, 1583-1591.	1.9	37
126	Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. <i>Journal of Viral Hepatitis</i> , 2018, 25, 134-143.	1.0	27
127	Eliminating hepatitis C within low-income countries – The need to cure genotypes 4, 5, 6. <i>Journal of Hepatology</i> , 2018, 68, 814-826.	1.8	35

#	ARTICLE	IF	CITATIONS
128	Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 421-431.	1.9	86
129	Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance. <i>Current Drug Metabolism</i> , 2018, 19, 215-223.	0.7	5
130	Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 2117-2127.	1.1	8
131	Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. <i>Pharmacogenomics</i> , 2018, 19, 979-995.	0.6	2
132	Interferon Lambda and Liver Fibrosis. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 627-635.	0.5	8
133	Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. <i>Immunologic Research</i> , 2019, 67, 123-133.	1.3	4
134	Polymorphism in interferon γ 3/interleukin 28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. <i>Journal of Medical Virology</i> , 2019, 91, 659-667.	2.5	9
135	Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients. <i>Genes and Diseases</i> , 2020, 7, 392-400.	1.5	13
136	Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review. <i>Pharmaceutics</i> , 2020, 12, 809.	2.0	23
137	A review of clinical pharmacogenetics Studies in African populations. <i>Personalized Medicine</i> , 2020, 17, 155-170.	0.8	35
138	The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 253-263.	0.4	0
139	Predictive power of Interleukin 28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101480.	0.7	0
140	Egypt: Towards Successful Elimination of HCV in Low-Income Countries. , 2021, , 229-235.		0
141	Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 942-949.	0.7	1
142	Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?. <i>Journal of General Virology</i> , 2016, 97, 2592-2598.	1.3	2
143	Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. <i>World Journal of Clinical Cases</i> , 2015, 3, 210.	0.3	10
144	Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico. <i>PLoS ONE</i> , 2016, 11, e0146258.	1.1	26
145	Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4. <i>Annals of Gastroenterology</i> , 2018, 32, 93-98.	0.4	2

#	ARTICLE	IF	CITATIONS
146	Impact of Interleukin 28B and ICAM-1 Genetic Polymorphisms on Response to Direct Antiviral Treatment Among HCV Infected Patients. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 1328-1335.	0.6	3
147	Association of C-myc and p53 Gene Expression and Polymorphisms with Hepatitis C (HCV) Chronic Infection, Cirrhosis and Hepatocellular Carcinoma (HCC) Stages in Egypt. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 2049-2057.	0.5	5
148	Impact of Interleukin-28B gene polymorphism [rs12979860] on Egyptian patients infected with hepatitis C virus genotype-4. <i>Eastern Mediterranean Health Journal</i> , 2013, 19, 98-104.	0.3	1
149	Interleukin-28 <i>i></i> and hepatitis C virus genotype-4: Treatment-induced clearance and liver fibrosis. <i>World Journal of Gastroenterology</i> , 2012, 18, 7003.	1.4	16
150	Individualization of chronic hepatitis C treatment according to the host characteristics. <i>World Journal of Gastroenterology</i> , 2014, 20, 2839.	1.4	9
151	Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. <i>World Journal of Gastroenterology</i> , 2015, 21, 8293.	1.4	24
152	Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. <i>World Journal of Hepatology</i> , 2015, 7, 725.	0.8	47
153	The Effect of IL28B Gene Polymorphism on Treatment Response in Iranian Patients with Hepatitis C Virus Infection. <i>Jundishapur Journal of Microbiology</i> , 2016, 9, .	0.2	1
154	IL28B rs12979860 Gene Polymorphism in Egyptian Patients with Chronic Liver Disease Infected with HCV. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 7213-7218.	0.5	10
155	Type 1 IFN-alpha Receptor Expression in Peripheral Blood Lymphocytes Independently Predicts Sustained Virological Response in Chronic Hepatitis C Genotype 1b with High Viral Load. <i>Journal of Blood & Lymph</i> , 2012, 02, .	0.0	0
156	Hepatitis C Virus Testing. , 2014, , 57-80.		0
157	Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response. <i>Journal of Clinical and Translational Hepatology</i> , 2013, 1, 39-44.	0.7	4
158	Genotype 4 Hepatitis C Virus Responds Worse than Genotype 1 to 48-Week Combination Treatment with Pegylated Interferon Alpha Plus Ribavirin: a Greek Multi-Centered Study. <i>Journal of Antivirals & Antiretrovirals</i> , 2014, S3, .	0.1	0
159	IL28B Genotyping: A Step towards HCV-Personalized Therapy. <i>International Journal of Gastroenterology Research and Practice</i> , 0, , 1-16.	0.0	0
160	Programmed Cell Death-1 Polymorphism rs11568821 is a predictor of Treatment Outcome in Chronic HCV Genotype 4 Infection. <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2015, 2, .	0.0	0
161	Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority. <i>The Egyptian Journal of Hospital Medicine</i> , 2019, 77, 4742-4747.	0.0	4
162	Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. <i>Hippokratia</i> , 2014, 18, 57-64.	0.3	5
163	Case study of hepatitis C virus control in Egypt: impact of access program. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675.	0.6	6

#	ARTICLE	IF	CITATIONS
164	Favorable Genotypes of Type III Interferon Confer Risk of Dyslipidemia in the Population With Obesity. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1